Melayna Lokosky is a corporate fraud expert and market analyst. Lokosky, a federal whistleblower, helped the U. S. Department of Justice (DOJ) recover $18M from her employer, Johnson & Johnson subsidiary Acclarent in less than five years, when a typical federal whistleblower case takes up to nine. As the first federal whistleblower in U.S. history to write publicly about her active case without breaking the federal seal, Lokosky held both DOJ and J&J accountable to the taxpayers while educating the public about the effects of venture capital-funded fraud.
Lokosky negotiated for six months with the DOJ to ensure Johnson & Johnson’s name appeared in the DOJ press release, a vital and precedent-setting detail which forced J&J accountability via SEO and prevented the parent company from distancing itself from subsidiary crimes in which they were complicit.
As a result of Lokosky’s case, former Acclarent executives were arrested, indicted, and convicted of 10 misdemeanors and are currently awaiting federal sentencing.
The last thing voting taxpaying citizens should want is anyone from venture capital anywhere near politics, much less the FDA, writes a corporate fraud analyst and federal whistleblower.
A federal whistleblower believes that the innovation cycle involving fundraising from venture capitalists and the pressure to hit revenue targets in the hopes of making an exit is the perfect recipe for corporate fraud.
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.